

DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School,
Makarba, Ahmedabad – 380 055

E-mail: dharachem99@yahoo.in

Date: 2nd July, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai –400 001.

Dear Sir / Madam,

Sub: Integrated Filing (Financial) for the Quarter and Year ended on 31st March, 2026


Ref: Symbol: DPL/ Code: 543594

Pursuant to the Securities and Exchange Board of India Circular No SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, please find attached the Integrated Filing (Financial) for the Quarter and Year ended March 31, 2026.

Kindly take the same on your record and oblige us.

Thanking You

For, Dipna Pharmachem Limited


Keyur Dipakkumar Shah
Managing Director
DIN: 03167258



A. Financial Result

| DIPNA PHARMACHEM LIMITED | | | | | | | |
|---|--|----------------|-------------------|-----------------|------------------|------------------|---------------------|
| CIN : LZ4100GJ2011PLC066400 | | | | | | | |
| Add: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad, Gujarat, India, 380055 | | | | | | | |
| Phone No :- 9898066121 | | | | | | | |
| Email id :- dharachem99@yahoo.in / info@dipnapharmachem.com | | | | | | | |
| STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE THREE MONTHS AND YEAR ENDED ON 31ST MARCH, 2026 | | | | | | | |
| (Amount Rs. in Lakhs) | | | | | | | |
| Sr. No | Particulars | Quarter ended | | | Year ended | | Previous Year ended |
| | | March 31, 2026 | December 31, 2025 | March 31, 2025 | March 31, 2026 | March 31, 2025 | March 31, 2025 |
| | | (Audited) | (Unaudited) | (Audited) | (Audited) | (Audited) | (Audited) |
| 1 | Income | | | | | | |
| | Revenue from operations | | | | | | |
| | a. Sale of Products and Services | 202.49 | 5,351.72 | 1,591.68 | 12,908.33 | 12,491.71 | 12,491.71 |
| | b. Other operating income | 2.54 | - | - | 2.54 | 1.28 | 1.28 |
| | Other Income | | | | | | |
| | Total Income | 205.03 | 5,351.72 | 1,591.68 | 12,910.87 | 12,492.99 | 12,492.99 |
| 2 | Expenses | | | | | | |
| | a. Purchase of stock-in-trade | 1,354.20 | 3,944.66 | 973.77 | 12,237.20 | 10,378.03 | 10,378.03 |
| | b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade | (1,542.76) | 758.80 | 50.67 | (1,489.05) | 994.69 | 994.69 |
| | c. Employee benefits expense | 10.37 | 10.36 | 9.63 | 41.12 | 41.74 | 41.74 |
| | d. Finance costs | 23.14 | 23.38 | 60.18 | 146.32 | 231.99 | 231.99 |
| | e. Depreciation and amortization expense | 0.44 | 0.45 | 0.29 | 1.43 | 1.14 | 1.14 |
| | f. Other expenses | 336.98 | 470.52 | 428.72 | 1,614.90 | 702.18 | 702.18 |
| | g. Power and Fuel | 0.38 | 2.02 | 0.67 | 4.47 | 1.20 | 1.20 |
| | Total Expenses | 182.75 | 5,210.19 | 1,523.93 | 12,556.39 | 12,350.97 | 12,350.97 |
| 3 | Profit before Exceptional items and tax (1-2) | 22.28 | 141.53 | 67.75 | 354.48 | 142.02 | 142.02 |
| 4 | Exceptional items | - | - | - | - | - | - |
| 5 | Profit before tax (3-4) | 22.28 | 141.53 | 67.75 | 354.48 | 142.02 | 142.02 |
| 6 | Tax expense | | | | | | |
| | a. Current Tax | 4.77 | 37.32 | 17.62 | 91.66 | 44.63 | 44.63 |
| | b. Deferred Tax | (0.35) | - | - | (0.37) | (0.01) | (0.01) |
| | Total Tax Expense | 4.42 | 37.32 | 17.62 | 91.29 | 44.62 | 44.62 |
| 7 | Net profit/(Loss) for the period (5-6) | 17.86 | 104.21 | 50.13 | 263.19 | 97.40 | 97.40 |
| 8 | Other Comprehensive income | | | | | | |
| | (Item that will not be reclassified to profit or loss (net of tax)) | - | - | - | - | - | - |
| 9 | Total Comprehensive income (after taxes) (7+8) | 17.86 | 104.21 | 50.13 | 263.19 | 97.40 | 97.40 |
| 10 | Paid up equity share capital (Face value of Rs.10/- each) | 2,628.92 | 2,628.92 | 2,404.53 | 2,628.92 | 2,404.53 | 2,404.53 |
| 11 | Other equity (Reserves) | 1,774.39 | 1,774.39 | 1,444.75 | 1,774.39 | 1,444.75 | 1,444.75 |
| 12 | Earning per equity share | | | | | | |
| | a. Basic | 0.07 | 0.40 | 0.21 | 1.00 | 0.41 | 0.41 |
| | b. Diluted | 0.07 | 0.40 | 0.21 | 1.00 | 0.41 | 0.41 |

Notes:

1. Number of Investors companies received, disposed of and lying unresolved as on 31.03.2026: Nil
2. The above results have been reviewed by audit committee and approved by the Board of Directors at their meeting held on 2nd July, 2026
4. The Company does not have any subsidiary company.
5. The Company has, for the first time adopted IND AS during the period and accordingly the above Audited Financial Results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under.
6. As the Company is having two segments during the year i.e. Steel & Chemicals segment, there are reportable segment in accordance with the requirement of IND AS-108 "Segment Reporting" specified under Section 133 of the Companies Act, 2013.

Place : Ahmedabad
Date : 02-07-2026



For, Dipna Pharmachem Ltd.
(Signature)
Keyur Shah
Managing Director
DIN:03167258



| Dipna Pharmachem Limited | | |
|--|------------------|-----------------------|
| CIN : L24100GJ2011PLC066400 | | |
| Add: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad, Gujarat, India, 380055 | | |
| Phone No :- 9898066121 | | |
| Email Id :- dharachem99@yahoo.in / info@dipnapharmachem.com | | |
| Balance Sheet as at 31st March, 2026 | | |
| | | (Amount Rs. in Lakhs) |
| Particulars | As at 31/03/2026 | As at 31/03/2025 |
| (1) ASSETS | | |
| Non-current assets | | |
| (a) Property, Plant and Equipment | 7.23 | 4.59 |
| (b) Capital work-in-progress | 0.00 | 0.00 |
| (c) Investment Property | 0.00 | 0.00 |
| (d) Goodwill | 0.00 | 0.00 |
| (e) Other Intangible assets | 0.00 | 0.00 |
| (f) Intangible assets under evelopment | 0.00 | 0.00 |
| (g) Biological Assets other than bearer plants | 0.00 | 0.00 |
| (b) Financial Assets | 0.00 | 0.00 |
| (i) Investments | 0.00 | 0.00 |
| (ii) Loans | 5116.42 | 4070.13 |
| (ii) Deferred Tax Asset (net) | 0.66 | 0.29 |
| (iv) Others | 29.64 | 29.07 |
| (c) Deferred tax assets (net) | 0.00 | 0.00 |
| (j) Other non-current assets | 0.00 | 0.00 |
| | 5153.95 | 4104.07 |
| Current assets | | |
| (a) Inventories | 4232.54 | 2743.49 |
| (b) Financial Assets | 0.00 | 0.00 |
| (i) Investments | 0.00 | 0.00 |
| (ii) Trade receivables | 4800.45 | 4733.06 |
| (iii) Cash and cash equivalents | 86.30 | 42.57 |
| (iv) Bank balances other than (iii) above | 32.90 | 39.31 |
| (v) Loans and Advances | 0.00 | 0.00 |
| (vi) Current Tax Assets (Net) | 0.00 | 0.00 |
| (vii) Other current assets | 6256.80 | 1575.53 |
| | 15408.99 | 9133.96 |
| Total Assets | 20562.94 | 13238.03 |
| EQUITY AND LIABILITIES | | |
| Equity | | |
| (a) Equity Share capital | 2628.92 | 2404.53 |
| (b) Other Equity | 1774.39 | 1444.75 |
| (c) Share warrant money received | 1827.01 | 0.00 |
| | 6230.32 | 3849.28 |
| LIABILITIES | | |
| Non-current liabilities | | |
| (a) Financial Liabilities | 0.00 | 0.00 |
| (i) Borrowings | 1010.01 | 1101.51 |
| (ii) Trade payables | 0.00 | 0.00 |
| (iii) Other financial liabilities (other than those specified in item (b), to be specified) | | 0.00 |
| (b) Provisions | 0.00 | 0.00 |
| (c) Deferred tax liabilities (Net) | | 0.00 |
| (c) Other non-current liabilities | 0.00 | 0.00 |
| (d) Deferred Tax Liability (net) | 0.00 | 0.00 |
| | 1010.01 | 1101.51 |
| Current liabilities | | |
| Financial Liabilities | | |
| (i) Borrowings | 311.09 | 620.90 |
| (ii) Trade payables | 0.00 | 0.00 |
| (iii) Other financial liabilities (other than those specified in item (c)) | 0.00 | 0.00 |
| (b) Other current liabilities | | |
| a. total outstanding dues of micro enterprises and small enterprises; and | 9210.18 | 4085.51 |
| b. total outstanding dues of creditors other than micro enterprises and small enterprises | 1824.08 | 3049.46 |
| Provisions | | 0.00 |
| (c) Current Tax Liabilities (Net) | 117.78 | 54.19 |
| (d) Other Current Liabilities | 1859.48 | 477.20 |
| Total Current Liability | 13322.60 | 8287.24 |
| Total Equity and Liabilities | 20562.94 | 13238.03 |

For and on behalf of the Board of Directors of
Dipna Pharmachem Ltd.



Keyur Shah
Keyur Shah
Managing Director
DIN:03167258

Place: Ahmedabad
Date: 02/07/2026

| Dipna Pharmachem Limited | | |
|--|-------------------|-------------------|
| CIN : L24100GJ2011PLC066400 | | |
| Add: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad, Gujarat, India, 380055 | | |
| Phone No :- 9898066121 | | |
| Email Id :- dharachem99@yahoo.in / info@dipnapharmachem.com | | |
| Cashflow Statement for the period ended on 31st March, 2026 | | |
| (Amounts in Lacs) | | |
| Particulars | 2025-26 | 2024-25 |
| Cash flow from operating activities: | | |
| Profit before tax from continuing operations | 354.48 | 142.02 |
| Adjustment to reconcile profit before tax to net cash flows | | |
| Bad Debt | 0.00 | 0.00 |
| Depreciation | 1.43 | 1.14 |
| Loss on sale of Property, Plant and Equipment | 0.00 | 0.00 |
| Finance Cost | 146.32 | 201.57 |
| Operating profit before working capital changes | 502.23 | 344.73 |
| Movements in working capital : | | |
| Increase/(decrease) in current liabilities & provisions | | |
| Decrease/(increase) in inventories | (1,489.05) | 994.69 |
| Decrease/(increase) in Trade Payables | 3,899.30 | 118.95 |
| Decrease/(increase) in Debtors | (67.39) | (1,533.90) |
| Decrease/(increase) in other current assets | (5,721.72) | (752.54) |
| Increase /(Decrease) in Other Current Liabilities | 1,072.47 | 19.89 |
| Increase /(Decrease) in Short Term Provisions | 63.59 | (66.65) |
| Cash Generated from/(used in) operations | (1,740.57) | (874.83) |
| Direct Taxes paid (net of refunds) | 91.66 | 44.63 |
| Net cash flow from /(used in) operating activities (A) | (1,832.23) | (919.46) |
| Cash flow from investing activities | | |
| Purchase of fixed assets | (4.07) | (2.01) |
| Sales of fixed assets | - | - |
| Investment | - | - |
| Net cash flow from/(used in) investing activities (B) | (4.07) | (2.01) |
| Cash flow from financing activities | | |
| Proceed from issue of Equity shares | 224.39 | |
| Proceed from Issue of share warrants | 1,827.01 | |
| Proceed from Share Premium | 66.45 | - |
| Increase / (Decrease) in Secured Borrowings | (91.50) | (222.22) |
| Increase / (Decrease) in Unsecured Borrowings | | - |
| Interest Paid | (146.32) | (201.57) |
| Net cash flow from/(used in) financing activities (C) | 1,880.03 | (423.79) |
| Net increase/decrease in cash & cash equivalents (A+B+C) | 43.73 | (1,345.26) |
| Cash & cash equivalents at the beginning of the year | 42.57 | 1,387.83 |
| Cash & cash equivalents at the end of the year | 86.30 | 42.57 |
| For and on behalf of the Board of Directors of Dipna Pharmachem Ltd. | | |
|   Keyur Shah Managing Director DIN:03167258 | | |
| Place: Ahmedabad | | |
| Date- 02/07/2026 | | |

| DIPNA PHARMACHEM LIMITED | | | | | | | |
|--|--|------------------|-------------------|-----------------|------------------|------------------|---------------------|
| CIN : L24100GJ2011PLC066400 | | | | | | | |
| Add: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad, Gujarat, India, 380055 | | | | | | | |
| Phone No :- 9898066121 | | | | | | | |
| Email Id :- dharachem99@yahoo.in / info@dipnapharmachem.com | | | | | | | |
| SEGMENT WISE STANDALONE REVENUE, RESULTS, ASSETS AND LIABILITIES | | | | | | | |
| (Amount Rs. in Lakhs) | | | | | | | |
| Sr. No | Particulars | Quarter ended | | | Year ended | | Previous Year ended |
| | | March 31, 2026 | December 31, 2025 | March 31, 2025 | March 31, 2026 | March 31, 2025 | March 31, 2025 |
| | | (Audited) | (Unaudited) | (Audited) | (Audited) | (Audited) | (Audited) |
| 1 | Income | | | | | | |
| | Segment Revenue from operations | | | | | | |
| | a. Sale of Products and Services | | | | | | |
| | Chemicals Segment | 202.49 | 2,625.04 | 10.93 | 5,819.19 | 10,910.96 | 10,910.96 |
| | Steel Segment | - | 2,726.68 | 1,580.75 | 7,089.14 | 1,580.75 | 1,580.75 |
| | Total Segment Revenue | 202.49 | 5,351.72 | 1,591.68 | 12,908.33 | 12,491.71 | 12,491.71 |
| 2 | Segment Results | | | | | | |
| | a. Chemicals Segment | (61.08) | (182.43) | 50.03 | (512.35) | 124.30 | 124.30 |
| | b. Steel Segment | 83.36 | 323.96 | 17.72 | 866.83 | 17.72 | 17.72 |
| | Total Segment Result | 22.28 | 141.53 | 67.75 | 354.48 | 142.02 | 142.02 |
| 3 | Segment Assets | | | | | | |
| | a. Chemicals Segment | 4,081.36 | 4,569.87 | 4,546.62 | 4,081.36 | 4,546.62 | 4,546.62 |
| | b. Steel Segment | 719.09 | - | 186.44 | 719.09 | 186.44 | 186.44 |
| | Total Segment Assets | 4,800.45 | 4,569.87 | 4,733.06 | 4,800.45 | 4,733.06 | 4,733.06 |
| 4 | Segment Liabilities | | | | | | |
| | a. Chemicals Segment | 8,935.98 | 7,647.44 | 6,958.33 | 8,935.98 | 6,958.33 | 6,958.33 |
| | b. Steel Segment | 2,098.28 | - | 176.64 | 2,098.28 | 176.64 | 176.64 |
| | Total Segment Liabilities | 11,034.26 | 7,647.44 | 7,134.97 | 11,034.26 | 7,134.97 | 7,134.97 |

Place : Ahmedabad
Date : 02-07-2026



For, Dipna Pharmachem Ltd.

Keyur Shah

Keyur Shah
Managing Director
DIN:03167258



Independent Auditor's Report on Audited Standalone Half Yearly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

INDEPENDENT AUDITOR'S REPORT

**TO THE BOARD OF DIRECTORS OF
DIPNA PHARMACHEM LIMITED**

Report on the audit of the Standalone Financial Results

Opinion


We have audited the accompanying standalone quarterly financial results of Dipna Pharmachem Limited ("the Company") for the quarter ended on 31st March, 2026 and the year to date results for the period from 1st April, 2025 to 31st March, 2026 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended on 31st March, 2026 as well as the year to date results for the period from 1st April, 2025 to 31st March, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.





Emphasis of Matter Paragraph

Our opinion is not modified in respect of this matter.

Management's Responsibilities for the Standalone Financial Results

These standalone quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:





DEVADIYA & ASSOCIATES

CHARTERED ACCOUNTANTS

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all Relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For, Devadiya & Associates
Chartered Accountants
FRN: 123045W

CA Sanjay Devadiya
Partner
Membership No. 112495
UDIN: 26112495PODYPB8261
Date: 2ND July, 2026
Place: Ahmedabad



DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba,
Ahmedabad - 380 055

E-mail: dharachem99@yahoo.in

Date: 2nd July, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai - 400 001.

Dear Sir / Madam,

**Sub: Declaration in respect of Unmodified Opinion on Audited Financial Result for the
Half year and Financial Year ended on 31st March, 2026**

Ref: Security Id: DPL / Code: 543594

We hereby declared that the Statutory Auditor of the Company, M/s. Devadiya & Associates, Chartered Accountants, has issued Audit Report with Unmodified Opinion on Audited Financial Result for the Half Year and Financial Year ended as on 31st March, 2026.

The declaration is given in compliance to second proviso of Reg. 33(3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment), Regulations 2016, vide notification no. SEBI/LAD-NRO/GN/2016-17/001, dated 25th May, 2016.

Kindly take the same on your record and oblige us.

Thanking You.

For, Dipna Pharmachem Limited


Keyur Dipakkumar Shah
Managing Director
DIN: 03167258



DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba,
Ahmedabad – 380 055

E-mail: धारारुकेडु99@yahoo.in

Statement of Deviation or Variation in Utilization of Funds Raised through Preferential Issue

| | |
|--|---|
| Name of listed entity | Dipna Pharmachem Limited |
| Mode of Fund Raising | Preferential Issue – Convertible Warrants |
| Date of Raising Funds | 24 th February, 2025 |
| Amount Raised | Allotment of 22,44,000 Equity shares pursuant to conversion of convertible warrants against the receipt of Rs. 2,19,63,150.00/- in the Board Meeting held on 29 th November, 2025, which together represent 75.00% of the total consideration for the issue. |
| Report filed for Quarter ended | 31-03-2026 |
| Monitoring Agency | Not Applicable |
| Monitoring Agency Name, if applicable | Not Applicable |
| Is there a Deviation / Variation in use of funds raised | No |
| If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the Unit holders | Not Applicable |
| If Yes, Date of Unit holders Approval | Not Applicable |
| Explanation for the Deviation / Variation | Not Applicable |
| Comments of the Audit Committee after review | None |
| Comments of the auditors, if any | None |

Set forth below are objects for which funds have been raised and where there has been a deviation, in the following table:

| Object for utilization of Issue Proceeds | Modified Object, if any | Original Allocation (Amount in Lakh) | Modified Allocation if any | Funds Utilised (Amount in Lakh)* | Amount of Deviation/ Variation for Quarter according to applicable object | Remarks if any |
|--|-------------------------|--------------------------------------|----------------------------|----------------------------------|---|----------------|
| To Meet Working Capital Requirements | N.A. | Rs. 7497.71/- | Rs. 5679.93/- | Rs. 1584.71/- | - | N.A. |
| General Corporate Purpose | N.A. | Rs. 2499.24/- | Rs. 1893.31/- | Rs. 528.24/- | - | N.A. |

DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba,
Ahmedabad – 380 055

E-mail: dharachem99@yahoo.in

**The Company received 25.00% of the total consideration for 5,80,32,500 convertible warrants at a price of Rs. 13.05/- per warrant, aggregating to Rs. 18,93,31,031/-, in the Board Meetings held on 9th September 2025 and 12th September 2025.*

**The Company received 75.00% of the total consideration for 22,44,000 equity shares, allotted pursuant to the conversion of warrants at a price of Rs. 13.05/- per share, aggregating to Rs. 2,19,63,150/-, in the Board Meeting held on 29th November 2025.*

We further certify that there are **no deviation(s) or variation(s)** in respect of the utilization of the funds of Preferential issue of Convertible Warrants ("Warrants") of the Company during the **Half and year ended on 31st March, 2026.**

Deviation or variation could mean:

- A. Deviation in the objects or purposes for which the funds have been raised or
- B. Deviation in the amount of funds actually utilized as against what was originally disclosed or
- C. Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc.

For, Dipna Pharmachem Limited



Keyur Dipakkumar Shah
Managing Director
DIN: 03167258



DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School,
Makarba, Ahmedabad – 380 055

E-mail: धारारुकेम99@यहू.इं

E. Statement on Impact of Audit Qualifications (For Audit Report with Modified Opinion) Submitted Along-with Annual Audited Financial Results (Standalone and Consolidated Separately) (Applicable only for Annual Filing i.e., 4th Quarter):

- Not Applicable